Business Context and Reporting Period
This Form 8-K is a current report filed by Xenomics, Inc. (not Cardiff Oncology, Inc.) on January 16, 2006. The registrant is incorporated in Florida with principal executive offices in New York, New York. The filing reports specific corporate governance events occurring on the date of the report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and bylaw amendments rather than financial performance.
Material Changes
- Appointment of Principal Officer: On January 16, 2006, the Company appointed Frederick Larcombe as Chief Financial Officer. Mr. Larcombe brings prior experience as CFO for MicroDose Technologies, Inc. and ProTeam.com, Inc., and consulting experience with Jefferson Wells and Kroll Zolfo Cooper.
- Amendment to Bylaws: The Board of Directors amended Article II, Section 2 of the Amended and Restated Bylaws. The amendment changes the scheduling of the annual shareholders' meeting from a fixed date (May 15) to a time and place designated by the Chairman of the Board of Directors.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to the disclosure of the CFO appointment and the bylaw amendment.
Investor Verification Checklist
- Verify the professional background and prior employment history of the newly appointed CFO, Frederick Larcombe.
- Confirm the implications of the bylaw amendment regarding the flexibility of scheduling future annual shareholder meetings.
- Note the discrepancy between the requested company name (Cardiff Oncology, Inc.) and the actual registrant in the filing (Xenomics, Inc.).